Effects of different periods of lithium pretreatment and aminoglycoside antibiotics on apomorphine-induced yawning in rats.
Interactive effects of intracerebroventricular administration of the aminoglycoside antibiotics, amikacin and gentamicin, and different duration of lithium pretreatment on apomorphine-induced yawning were investigated in male rats. The study was designed to investigate whether the hypothesis that the aminoglycoside antibiotics, amikacin and gentamicin, via their effects on phosphoinositide pathways and calcium channel might influence dopaminergic mechanisms as manifested in the yawning effect. Lithium is known to interact with phosphoinositide metabolism and was also tested after chronic studies on the apomorphine yawning model. Subcutaneous administration of apomorphine (0.1, 0.2 and 0.4 mg/kg) to rats induced yawning in a biphasic manner. However the maximum response was obtained by 0.2 mg/kg of the drug. Intracerebroventricular administration of aminoglycoside antibiotics amikacin (25 microg/rat) increased and gentamicin (10 and 20 microg/rat) decreased apomorphine-induced yawning. Pretreatment of animals with lithium (600 mg/l) in drinking water for 7, 14 and 21 days reduced yawning induced by apomorphine. Administration of lithium for 28 days did not induce any significant effect on yawning response. Amikacin and gentamicin function via the same mechanism on phosphoinositide cascade. Since amikacin and gentamicin did not affect the yawning response similarly, they apparently do not involve inositol trisphosphate level in the alterations of dopaminergic-induced yawning. Probably, the effect of lithium pretreatment on the number of yawns is also time-dependent and some tolerance to the inhibitory effect of lithium might occur after 28 days' treatment.
Sharifzadeh
M
M
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Iran. mosharifzad@yahoo.com
Firooz
E K
EK
Abdollahi
M
M
D000583:Amikacin / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001058:Apomorphine / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D018491:Dopamine Agonists / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004347:Drug Interactions; D005839:Gentamicins / Q000008:administration & dosage / Q000627:therapeutic use*; D007276:Injections, Intraventricular; D008094:Lithium / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D015000:Yawning / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D018491:Dopamine Agonists; D005839:Gentamicins; D000583:Amikacin; D008094:Lithium; D001058:Apomorphine